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Purpose: The purpose of this study was to compare the visibility of breast tissue markers in cases 
of breast cancer on ultrasonography (US) after neoadjuvant chemotherapy (NAC) and to analyze 
whether the type of marker affected the choice of localization method after NAC.
Methods: We included 153 tissue markers inserted within breast cancers that showed 
pathologically complete response (pCR) after NAC from January 2012 to April 2017. One of 
three types of markers (a surgical clip, Cormark, or UltraClip) was inserted. Medical records 
and imaging findings were retrospectively reviewed. We compared the visibility of the different 
types of tissue markers on US after NAC, and also compared the imaging modalities used in the 
preoperative localization. The chi-square test, Fisher exact test, and multiple logistic regression 
were used for analysis. 
Results: Of the 153 tissue markers, 56 were surgical clips, 61 Cormark, and 36 UltraClip. After 
NAC, residual lesions were not seen on US in 42 cases (27.5%). In multivariate analysis, the 
visibility of the surgical clips and Cormark markers was better than that of the UltraClip markers 
(odds ratio [OR], 5.467; 95% confidence interal [CI], 1.717 to 17.410; P=0.004 and OR, 3.045; 
95% CI, 1.074 to 8.628; P=0.036, respectively). Among the 131 cases where localization 
targeting the marker was required, the proportion of US-guided localizations was significantly 
higher when a surgical clip was used than when an UltraClip marker was used (OR, 5.566; 95% 
CI, 1.610 to 19.246; P=0.007) in the multivariate analysis.
Conclusion: The type of breast tissue marker affected its visibility on US in cases with pCR after 
NAC, which in turn affected the localization methodology.
Keywords: Breast; Ultrasonography; Localization; Surgical clip 
Introduction
Neoadjuvant chemotherapy (NAC) is widely considered in breast cancer patients who are potential 
candidates for adjuvant chemotherapy [1]. NAC has been proven to increase overall survival and 
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disease-free survival, while providing an increased chance of being 
able to perform breast-conserving surgery (BCS) [2]. The safety and 
efficacy of breast tissue marker insertion before NAC are now also 
commonly accepted. Markers are used to demarcate the biopsy area 
because a residual tumor after NAC may be clinically occult and 
further surgery may be required pending a margin status review by 
pathology. The placement of these markers is more accurately done 
under ultrasound (US) guidance than under stereotactic guidance 
[3,4]. 
When BCS is considered, needle localization is necessary for 
marker insertion prior to surgery. A marker may be clearly visible 
on US if it is present within a hypoechoic lesion, and US-guided 
localization is preferred because US-guided biopsy has several 
advantages over stereotactic biopsy [5]. However, in patients with 
pathologically complete response (pCR), the lesions might have 
dramatically shrunk to the point of not being visible on US. Well-
visible breast tissue markers need to be placed in these lesions in 
order to enable better surgical options and outcomes [3,6].
While Fajardo et al. [7] introduced the benefits of the microcoil as 
a breast marker, Thomassin-Naggara et al. [8] introduced surgical 
clips inserted with an 18-gauge spinal needle. Before many types 
of commercial breast tissue markers were available for patients 
undergoing NAC, surgical clips were used as breast markers. 
Breast tissue markers can be categorized into commercial metallic 
markers and markers with surrounding material. Commercial 
metallic markers are simply made of 2- to 3-mm pieces of titanium 
or stainless steel, and are the most commonly used markers today. 
Markers with surrounding material were developed for long-term 
visibility, and the embedding materials can be collagen, polylactic 
acid, polyglycolic acid or starch pellets, or hydrogel. These markers 
have several advantages. First, they fill the space cavity, thereby 
decreasing the risk of marker migration. Second, the markers have 
a hemostatic effect because they place direct pressure on adjacent 
tissue. Third, they enhance visibility on US. However, a previous study 
reported that although markers with a microfiber pad were clearly 
seen on US just after insertion, visibility greatly decreased after 
6-8 weeks, making them ineffective as breast markers for patients 
who have undergone NAC [8]. The effectiveness of surgical clip 
placement has been studied before for breast cancer, but insufficient 
studies have compared different types of breast tissue markers after 
NAC [9]. It is necessary to investigate which types of breast tissue 
markers are more visible on specific imaging modalities, because 
such knowledge would help radiologists determine the most suitable 
type of breast tissue marker for each patient before insertion.
The objective of this study was to compare the visibility of breast 
tissue markers after NAC on US and to analyze whether the type of 
breast tissue marker affected the choice of localization method.
Materials and Methods
This retrospective study was approved by the Institutional Review 
Board of our institution with a waiver of informed consent.
Fig. 1. Selection process for the study population. pCR, pathologic complete response.
717 Breast cancers with neoadjuvant 
chemotherapy & clip insertion
246 Breast cancers with 
pCR at surgery






471 Breast cancers with no pCR
93 Breast cancers without localization 
due to mastectomy or palpability
36 UltraClip
2016 Aug-2017 Apr
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Patients
From January 2012 to April 2017, we inserted breast tissue 
markers before NAC for 717 breast cancers that were biopsied 
under US guidance. Among them, 246 cases were confirmed to 
show pCR at surgery. While 153 of the pCR cases underwent BCS 
after localization, the remaining 93 underwent total mastectomy. 
The final study population consisted of patients confirmed to have 
achieved pCR who were treated by BCS (Fig. 1). pCR was defined 
as the absence of invasive cancer in both the breast and lymph 
nodes with or without the presence of ductal carcinoma in situ 
(DCIS) [1]. We retrospectively reviewed the patients’ medical records 
and recorded which of the three types of breast tissue marker was 
inserted: a surgical clip (LigaClip MCA MSM20, Ethicon Endo-
Surgery, Somerville, NJ, USA), an UltraClip marker (C. R. Bard Inc., 
Murray Hill, NJ, USA), or a Cormark marker (Ethicon Endo-Surgery 
Inc, Cincinnati, OH, USA) (Fig. 2). From January 2012 to February 
2015, LigaClip markers were inserted, and from March 2015 to July 
2016, Cormark markers were inserted. After August 2016, UltraClip 
markers were inserted. The clinicopathologic data for the three 
groups are given in Table 1.
Breast Tissue Marker Implantation
Markers were implanted just before NAC by one of 13 radiologists 
who subspecialized in breast imaging (Fig. 3). After local anesthesia 
was applied under aseptic dressing, a 14-gauge coaxial guiding 
needle was inserted into the breast cancer under US guidance. The 
Table 1. Comparison of clinicopathologic data for the patients who underwent breast tissue marker insertion
Parameter LigaClip (n=56) UltraClip (n=36) Cormark (n=61) P-value
Age, median  (interquartile range, yr) 52 (45.0-57.0) 47.5 (40.5-52.75) 51 (41.5-57.0) 0.143a)
Pathology
    Luminal A 3 2 4 0.565b)
    Luminal B 6 5 10
    HER+ 14 10 16
    TNBC 33 19 31
    pCR with DCIS 18 12 12 0.229c)
    pCR without DCIS 38 24 49
Dense breast type
    A 1 0 0 0.408b)
    B 9 4 9
    C 43 29 42
    D 3 3 10
HER, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; pCR, pathologic complete response; DCIS, ductal carcinoma in situ.
a)The Kruskal-Wallis test was used. b)The Fisher exact test was used. c)The Pearson chi-square test was used.
Fig. 2. Mammograms of three markers: LigaClip (A), Cormark (B), and UltraClip (C).
A B C
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inner stylet was pulled off and the breast tissue marker (LigaClip or 
Cormark) was inserted through an introducer. The inner stylet was 
then reinserted in order to insert the marker completely into the 
lesion. UltraClip markers were inserted without a coaxial guiding 
needle. We inserted one marker into each cancer lesion. US was 
used to confirm the location of the marker immediately after the 
implantation procedure. Mammography was also used to confirm 
the location of the marker.
Imaging Protocol and Assessment
Ultrasonography and mammography were used to evaluate breast 
cancer lesions just before starting NAC and before surgery. In 
the 148 patients, 153 lesions were identified on US just before 
NAC, and breast tissue markers were inserted into each lesion. 
The insertion of the marker was also confirmed by mammography. 
After each chemotherapy cycle was finished, the visibility of the 
tumor lesion and breast tissue markers was evaluated on both 
US and mammography, and these findings were recorded in the 
imaging reading reports. We considered a marker to be visible if 
it was indicated as visible in the imaging reading reports. All US 
examinations were performed by radiologists who subspecialized 
in breast imaging. The echogenicity of the surrounding background 
(hypoechoic, isoechoic, or hyperechoic) and marker depth were also 
analyzed. In cases where no marker was seen on US, echogenicity 
was measured in the presumed area and marker depth was 
measured on images taken immediately after marker insertion. 
A B
C D
Fig. 3. Visible LigaClip with ultrasound-
guided localization (no residual lesion) in 
a 50-year-old woman with triple-negative 
breast cancer and no ductal carcinoma in 
situ. 
A. Initial tumor lesion was seen on ultra-
sound with LigaClip. B. Only the LigaClip 
is visible on ultrasound after neoadjuvant 
chemotherapy. C. The localization needle is 
inserted into the lesion. D. Localization was 
confirmed using specimen mammogram. 
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The tumor lesions were localized before surgery. When the marker 
was clearly visible on US, it was localized under US guidance, 
and if the marker was not visible on US or if microcalcifications 
needed to be targeted through a mammogram, it was localized 
under mammography guidance. After surgery, we confirmed that 
the localization needle and markers had been removed through 
specimen mammograms.
Data Analysis
We retrospectively reviewed patients’ medical records to 
evaluate whether the breast tissue markers were visible on US or 
mammography. Localization methods in partial mastectomy patients 
were reviewed. Additionally, the surgical method and pathology 
reports from surgical specimens were reviewed. Estrogen receptor, 
progesterone receptor, human epidermal growth factor receptor 2 
(HER2), and Ki-67 were analyzed to categorize the pathologic type 
of breast cancer as triple-negative breast cancer (TNBC), luminal 
type A and B, or HER2+. The presence of DCIS was also reviewed.
Groups were compared regarding the visibility of the breast 
tissue marker on US after NAC and the methodology of localization 
using the chi-square test and the Fisher exact test. The relationships 
between marker visibility and the type of breast cancer pathology 
or presence of DCIS were also analyzed using the chi-square test 
and the Fisher exact test. We performed an analysis of all cases, 
then analyzed selected cases in which no residual lesion was seen 
on US. Furthermore, we conducted multiple logistic regression for 
the multivariate analysis. P-values less than 0.05 were considered 
to indicate statistical significance. SPSS version 23.0 (IBM Corp., 
Armonk, NY, USA) was used for statistical analysis. Patients were 
categorized by the type of breast tissue marker inserted.
Results
In 148 patients (median age, 51 years; range, 26 to 72 years) who 
underwent BCS after localization, three types of breast tissue markers 
were inserted in 153 breast lesions that demonstrated pCR at 
surgery: 56 LigaClip markers, 61 Cormark markers, and 36 UltraClip 
markers. At the US evaluations after NAC, a residual tumor lesion 
was seen in 111 cases (72.5%), but not in the remaining 42 cases 
(27.5%). Markers were seen on US in 127 cases overall (83.0%), and 
in 30 cases (71.4%) with no residual lesion visible on US.
 
Comparison of the Visibility of the Breast Tissue Marker by 
Type 
Marker visibility was significantly more common when using LigaClip 
(91.1%, 51 of 56) or Cormark markers (86.9%, 53 of 61) than when 
using UltraClip markers (63.9%, 23 of 36; P=0.002 and P=0.008, 
respectively) in all cases (Figs. 3-5). In cases where no residual 
lesion was noted on US after NAC, marker visibility was significantly 
more common when using LigaClip markers (88.2%, 15 of 17) 
than when using UltraClip markers (46.7%, 7 of 15, P=0.021). 
Marker visibility tended to be more common in cases using Cormark 
markers (80% [8 of 10]) than those using UltraClip markers (46.7%, 
7 of 15), but without statistical significance (P=0.211) (Table 2).
 
Clinicopathologic Factors Affecting the Visibility of the 
Breast Tissue Marker on US
Of the 153 breast lesions, nine were luminal A breast cancer, 21 
were luminal B breast cancer, 83 were TNBC, and 40 were HER2+ 
breast cancer. There were 42 cases with a residual DCIS component, 
and the remaining 111 did not have DCIS or an invasive component. 
The presence of residual DCIS and the molecular type of breast 
cancer did not affect the visibility of the breast tissue marker on US 
after NAC (P=0.845 and P=0.583, respectively). 
US Echogenicity and Marker Depth
Among the 153 cases, the surrounding background was categorized 
as hypoechoic in 67 cases and as isoechoic in 86 cases. Echogenicity 
Table 2. Comparison of visibility on ultrasound between breast tissue markers 
LigaClip UltraClip Cormark
Yes No Yes No Yes No
All cases (n=153) 56 36 61
    No. (%) 51 (91.1) 5 (8.9) 23 (63.9) 13 (36.1) 53 (86.9) 8 (13.1)
    P-value 0.002a) 0.008b)
No residual  lesion on ultrasound (n=42) 17 15 10
    No. (%) 15 (88.2) 2 (11.8) 7 (46.7) 8 (53.3) 8 (80.0) 2 (20.0)
    P-value 0.021a) 0.211b)
a)P-value for LigaClip and UltraClip. b)P-value for UltraClip and Cormark.  
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Fig. 5. Mammogram-guided localization due to the absence of a visible breast tissue marker (UltraClip) on ultrasonography (US) in a 
64-year-old woman with human epidermal growth factor receptor 2-positive breast cancer with no ductal carcinoma in situ. 
A. The marker is visible on mammography. B. A guided wire is located in the marker. C. No residual lesion or marker is visible on US after 
neoadjuvant chemotherapy. 
A B C
Fig. 4. Visible Cormark with ultrasound-guided localization (no residual carcinoma, 
fibrosis with collagen-like material deposition and giant cell reaction) in a 46-year-old 
woman with human epidermal growth factor receptor 2-positive breast cancer with 
residual ductal carcinoma in situ. 
A. Initial tumor lesion was seen on ultrasound with the marker. B. Only the Cormark (marker 
itself [arrow], adjacent collagen [arrowhead]) is visible on ultrasound after neoadjuvant 
chemotherapy. C. Localization was confirmed using specimen mammogram. 
A B
C
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did not affect visibility (P=0.891). The marker depth was 11.7±3.78 
mm (mean±standard deviation), and also did not affect visibility 
(P=0.084).
Comparison of Localization Methodology by Type of Breast 
Tissue Marker
Of the 153 breast lesions, 131 were analyzed to determine whether 
the type of breast tissue marker affected localization methodology. 
Other lesions (n=16) were localized by targeting microcalcifications 
on mammography (Fig. 5), and six cases were localized by targeting 
the tumor lesion, not the marker on US, because the marker was 
not visible on US. The marker was not targeted in these 22 cases, so 
they were excluded from this analysis. The percentage of US-guided 
localizations was significantly higher when using LigaClip markers 
(90.4%, 47 of 52) or Cormark markers (86.3%, 44 of 51) than when 
using UltraClip markers (60.7%, 17 of 28; P=0.003 and P=0.013, 
respectively) in all cases. The proportion of US-guided localizations 
was significantly higher when using LigaClip markers (81.3%, 13 
of 16) than when using UltraClip markers (38.5%, 5 of 13) in cases 
where no residual lesion was noted on US after NAC (P=0.027). 
The proportion of US-guided localizations was higher when using 
Cormark markers (75.0%, 6 of 8) than when using UltraClip markers 
(38.5%, 5 of 13) when no residual lesion was noted on US after 
NAC, but this trend did not reach statistical significance (P=0.183) 
(Table 3). The presence of DCIS and the molecular type of breast 
cancer did not affect the localization method after NAC (P=0.657 
and P=0.902, respectively). The echogenicity of the surrounding 
background and marker depth did not affect the localization method 
after NAC (P=0.397 and P=0.084, respectively).
Multivariate Analysis
We performed a multivariate analysis using multiple logistic 
regression (Tables 4, 5). In the univariate logistic regression analysis, 
the visibility of LigaClip or Cormark markers was better than 
that of UltraClip markers (P=0.003 and P=0.010, respectively), 
and marker visibility was better in cases with US-visible residual 
Table 3. Comparison of the localization methodology between breast tissue markers 
LigaClip UltraClip Cormark
US MG US MG US MG
All cases (n=131) 52 28 51
    No. (%) 47 (90.4) 5 (9.6) 17 (60.7) 11 (39.3) 44 (86.3) 7 (13.7)
    P-value 0.003a) 0.013b)
No residual lesion on US (n=37) 16 13 8
    No. (%) 13 (81.3) 3 (18.8) 5 (38.5) 8 (61.5) 6 (75.0) 2 (25.0)
    P-value 0.027a) 0.183b)
US, ultrasound; MG, mammography. 
a)P-value for LigaClip and UltraClip. b)P-value for UltraClip and Cormark.
Table 4. Univariate and multivariate analysis for visibility on US between breast tissue markers 
Variable
Univariate analysis Multivariate analysis
Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
LigaClip vs. UltraClip 5.765 (1.839-18.078) 0.003 5.467 (1.717-17.410) 0.004
Cormark vs. UltraClip 3.745 (1.367-10.256) 0.010 3.045 (1.074-8.628) 0.036
Residual lesion visible on US 2.771 (1.158-6.635) 0.022 2.430 (0.956-6.177) 0.062
Presence of DCIS 1.033 (0.399-2.670) 0.947 - -
Luminal A vs. TNBC 0.406 (0.091-1.819) 0.239 - -
Luminal B vs. TNBC 1.217 (0.315-4.699) 0.775 - -
HER+ vs. TNBC 1.150 (0.406-3.256) 0.793 - -
Age 1.029 (0.986-1.073) 0.195 - -
Marker depth 0.907 (0.812-1.013) 0.084 - -
Hypoechoic than isoechoic 0.891 (0.382-2.079) 0.790 - -
US, ultrasonography; OR, odds ratio; CI, confidence interval; DCIS, ductal carcinoma in situ; TNBC, triple-negative breast cancer; HER2, human epidermal growth factor receptor 2.
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lesions (P=0.022). The proportion of US-guided localizations was 
significantly higher with LigaClip or Cormark markers than with 
UltraClip markers (P=0.003 and P=0.012, respectively) and in cases 
with US-visible residual lesions (P=0.002).
In the multivariate analysis, the visibility of LigaClip or Cormark 
markers was better than that of UltraClip markers (P=0.004 and 
P=0.036, respectively), but the visibility of residual lesion on US did 
not significantly affect the visibility of the markers (P=0.062). The 
proportion of US-guided localizations was significantly higher when 
using LigaClip markers than when using UltraClip markers (P=0.007), 
but not when using Cormark markers in comparison to UltraClip 
markers (P=0.088). Additionally, the presence of a visible residual 
lesion on US favored US-guided localization (P=0.006). 
 
Discussion
NAC is an internationally recognized treatment option for breast 
cancer. The effect of NAC is dramatic in some patients, and the 
proportion of patients achieving pCR has been reported to be as 
high as 32.9% in some studies [10]. However, an excellent response 
to NAC can cause difficulties in localization because residual lesions 
are not clearly visible on images [3,11-13]. Dash et al. [11] reported 
that no residual tumors were visible on 35.7% of mammograms 
(10 of 28). Furthermore, Edeiken et al. [3] reported that 46.9% 
of lesions (23 of 49) were not visualized on US or mammography 
after NAC. In such cases, localization is almost impossible without a 
breast tissue marker. As localization is needed to decide the extent 
of surgery and to help the pathologist identify the main lesion, the 
implantation of breast tissue markers is important for breast cancer 
patients who undergo NAC.
The visibility of the breast tissue marker is important for 
localization. US, mammography, and magnetic resonance imaging 
(MRI) can all be used for localization, and almost all markers are 
visible on mammography and MRI. However, radiation hazards need 
to be considered with regard to mammogram-guided localization, 
and MRI-guided localization is difficult to perform due to excessive 
time and cost. Thus, US is the most feasible method for localization, 
but breast tissue markers have relatively inferior visibility on US 
compared to their visibility on mammography and MRI. In our study, 
28.6% of the markers (12 of 42) were not seen on US when no 
residual tumor was visible on US. This kind of non-visibility of breast 
tissue markers poses a clinical challenge.
As far as we know, very few studies have compared the visibility 
of different types of breast tissue markers [14]. Our study shows 
that the visibility of LigaClip and Cormark may be superior to that 
of UltraClip, although the use of surgical clips has decreased in 
recent years due to the introduction of commercial breast markers. 
LigaClip is thicker than other markers, which might be why it is 
clearly visible on US (Fig. 3). Cormark is a marker in which a metal 
clip is surrounded by collagen. The surrounding collagen provides 
extra contrast, allowing better visibility of the marker (Fig. 4). 
UltraClip is a marker composed of a non-absorbable polyvinyl 
alcohol (PVA) polymer with a metallic clip. Our results are broadly 
similar to those reported by Sakamoto et al. [15], who indicated 
that 60% of UltraClip markers were visible. The PVA polymer does 
not help enhance visibility, so fewer than 50% of UltraClip markers 
were visible on US when residual lesions were not visible on US in 
our study (Fig. 5). However, the surrounding collagen helps enhance 
visibility, so more than 80% of Cormark markers were visible. 
Therefore, radiologists should consider the fact that some markers 
Table 5. Univariate and multivariate analysis for US-guided localization compared to mammogram-guided localization between 
breast tissue markers 
Variable
Univariate analysis Multivariate analysis
Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
LigaClip vs. UltraClip 6.082 (1.843-20.070) 0.003 5.566 (1.610-19.246) 0.007
Cormark vs. UltraClip 4.067 (1.353-12.226) 0.012 2.772 (0.858-8.951) 0.088
Residual lesion visible on US 4.550 (1.776-11.659) 0.002 4.121 (1.497-11.349) 0.006
Presence of DCIS 0.800 (0.298-2.146) 0.658 - -
Luminal A vs. TNBC 0.609 (0.110-3.362) 0.570 - -
Luminal B vs. TNBC 0.880 (0.219-3.533) 0.857 - -
HER+ vs. TNBC 1.016 (0.328-3.145) 0.979 - -
Age 1.025 (0.980-1.072) 0.284 - -
Marker depth 0.924 (0.825-1.034) 0.170 - -
Hypoechoic vs. isoechoic 1.500 (0.587-3.833) 0.397 - -
US, ultrasonography; OR, odds ratio; CI, confidence interval; DCIS, ductal carcinoma in situ; TNBC, triple-negative breast cancer; HER2, human epidermal growth factor receptor 2.
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may not be visible after NAC if the tumors show a good response to 
NAC before inserting the marker. In our study, only 34% of cancers 
(246 of 717) reached pCR status, and among them, only 42 cases 
(27.5%, 42 of 153) were not visible on US after NAC. Because of 
the relatively small number of cases with no visible residual tumors, 
our study might not have an immediate clinical impact at this 
time, but continuing developments and improvements in NAC and 
targeted therapy may increase the number of pCR cases, so that our 
findings may gain more clinical importance in the future.
There are several limitations of this study. First, our study was 
retrospective, so selection bias may have been present. Second, 
the number of cases with no visible residual tumors was relatively 
small, although marker visibility was especially important in those 
cases. Finally, the visibility of the markers was evaluated on the basis 
of imaging reading reports written by many radiologists, so inter-
observer variability may have been present.
In conclusion, the type of breast tissue marker affected the 
visibility of the marker on US, and more importantly, the localization 
method used in breast cancer patients who underwent NAC. Thus, 
the type of breast tissue marker should be considered before clip 
insertion.
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